InvestorsHub Logo
Followers 0
Posts 10
Boards Moderated 0
Alias Born 07/24/2015

Re: None

Thursday, 08/25/2016 3:27:11 AM

Thursday, August 25, 2016 3:27:11 AM

Post# of 1315
2:39 am Prima Biomed receives European patent grants for its IMP731 antibody (PBMD) :

Co announces the granting of patent number 2142210 entitled "Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease" by the European Patent Office.
•The patent relates to Prima's IMP731 antibody. The granted claims provide protection for specific sequences of anti-LAG-3 antibodies and their use in depleting LAG-3+ T cells by complement dependent cytotoxicity and antibody-dependent cell cytotoxicity.
•Rights for the development of the IMP731 antibody were granted in December 2010 to GSK, which has commenced first-in-human clinical trials of the proprietary antibody (GSK2831781) derived from IMP731.